Anaid is developing a real-time DNA damage repair diagnostic test to assess the DNA repair capacity of tumor samples to help clinicians stratify patients into more effective treatment strategies.
NEWS
Following her participation in the outstanding Programme for Up and coming Life Sciences Entrepreneurs (PULSE) and WE ACE program, Anaid secured a place in the highly competitive Cancer Tech Accelerator programme Phase I. Launched by Cancer Research UK (CRUK), Capital Enterprise, and Roche UK, CTA forms part of a new initiative from CRUK’s Entrepreneurial Programmes and aims to help researchers translate their innovative ideas into lifesaving technologies for the benefit of cancer patients.